Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Use for Atherogenic Dyslipidemia in Solid Organ Transplant Patients
Journal of Clinical Medicine（2022）
Key words
dyslipidemia,immunosuppressants,transplant,PCSK9,PCSK9 inhibitors,alirocumab,evolocumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined